Google
Trusted Resources: Community Center
Online support, community stories, financial assistance
Prothena Corporation PLC – Linkedin
Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases. Fueled by its deep scientific understanding built over decades of neuroscience research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson’s disease and other related synucleinopathies (prasinezumab – PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, Aβ (Amyloid beta) and TDP-43 where its scientific understanding of disease pathology can be leveraged.
myBinderRelated Content
-
Talking With Your Doctor About hATTR AmyloidosisAre You Experiencing Symptoms and Suspec...
-
Rahma Warsame, MDDr. Rahma Warsame is an Associate Profes...
-
Virtual Meeting – Amyloidosis Support Groups – Saturday, July 15, 2023Date & Time Saturday, July 15, 2023...
-
The Rules of the Doctor’s HeartEvery medical case, to paraphrase the wr...
-
Present Troubles RacingPresent Troubles Racing is a non-profit ...
-
Rare Disease Day Symposium at the Quinnipiac Frank H. Netter MD School of MedicineThe Rare Disease Day Symposium at the Qu...
-
Webinar Event on Progress in Amyloidosis Research: Where Are We Now?Join a Live Webinar Event on “Prog...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
